{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:06:26Z","timestamp":1792065986650,"version":"4.4.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Avidity Biosciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Duchenne muscular dystrophy (DMD) is a severe disorder caused by mutations in the dystrophin gene, resulting in loss of functional dystrophin protein in muscle. While phosphorodiamidate morpholino oligomers (PMOs) are promising exon-skipping therapeutics aimed at restoring dystrophin expression, their effectiveness is often limited by poor muscle delivery. We developed AOC 1044, an antibody\u2013oligonucleotide conjugate (AOC) that combines a PMO-targeting exon 44 with an antibody against the transferrin receptor (TfR1), enhancing delivery to muscle tissues for patients with DMD amenable to exon 44 skipping (DMD44). AOC 1044 induces dose-dependent exon 44 skipping and its mouse-active variant elicited dose-dependent dystrophin restoration in skeletal and cardiac muscle in a DMD mouse model. This treatment also reduced muscle damage, as evidenced by decreases in serum creatine kinase and key liver enzymes, suggesting that restored dystrophin is functionally active. In nonhuman primates, single or repeated AOC 1044 doses resulted in dose-dependent increases in PMO concentration and exon 44 skipping across a range of muscle tissues, including the heart. Collectively, these findings highlight AOC 1044 as a promising therapeutic candidate for patients with DMD44, offering improved muscle targeting and meaningful dystrophin restoration, with potential clinical benefits in reducing muscle degeneration.<\/jats:p>","DOI":"10.1093\/nar\/gkaf241","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:24:00Z","timestamp":1742329440000},"source":"Crossref","is-referenced-by-count":23,"title":["AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-404X","authenticated-orcid":false,"given":"Usue","family":"Etxaniz","sequence":"first","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Marks","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Albin","sequence":"additional","affiliation":[{"name":"Seawolf Therapeutics, 9880 Campus Point Drive , Suite 210, San Diego , CA 92121 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Diaz","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard , 75 Ames Street, Cambridge , MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Anderson","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olecya","family":"Tyaglo","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Hoang","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Azzurra","family":"Missinato","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Svensson","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Badillo","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R","family":"Kovach","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Leung","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cochran","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Won","family":"Kwon","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Nur","family":"Ahad\u00a0Shah","sequence":"additional","affiliation":[{"name":"Yokota Lab, Department of Medical Genetics, University of Alberta ,\u00a0Edmonton,T6G 2H,\u00a0","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Yokota Lab, Department of Medical Genetics, University of Alberta ,\u00a0Edmonton,T6G 2H,\u00a0","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"Yokota Lab, Department of Medical Genetics, University of Alberta ,\u00a0Edmonton,T6G 2H,\u00a0","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata R","family":"Doppalapudi","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Darimont","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam\u00a0S","family":"Younis","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Michael","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A","family":"Levin","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanhua","family":"Huang","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Karamanlidis","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 10578 Science Drive, Suite 125, San Diego , CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"2025041601022992500_B1","doi-asserted-by":"publisher","first-page":"e0135189","DOI":"10.1371\/journal.pone.0135189","article-title":"DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations","volume":"10","author":"Juan-Mateu","year":"2015","journal-title":"PLoS One"},{"key":"2025041601022992500_B2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"2025041601022992500_B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025041601022992500_B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025041601022992500_B5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ana.24365","article-title":"Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45","volume":"77","author":"Findlay","year":"2015","journal-title":"Ann Neurol"},{"key":"2025041601022992500_B6","first-page":"54","article-title":"Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies","volume":"49","author":"Beggs","year":"1991","journal-title":"Am J Hum Genet"},{"key":"2025041601022992500_B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/117.1.1-a","article-title":"Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates","volume":"117","author":"Comi","year":"1994","journal-title":"Brain"},{"key":"2025041601022992500_B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/mt.2010.219","article-title":"The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy","volume":"19","author":"Lu","year":"2011","journal-title":"Mol Ther"},{"key":"2025041601022992500_B9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/156652312800840621","article-title":"Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges","volume":"12","author":"Arechavala-Gomeza","year":"2012","journal-title":"Curr Gene Ther"},{"key":"2025041601022992500_B10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2025041601022992500_B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N Engl J Med"},{"key":"2025041601022992500_B12","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"2025041601022992500_B13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"2025041601022992500_B14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2025041601022992500_B15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"2025041601022992500_B16","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"2025041601022992500_B17","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"2025041601022992500_B18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol Med"},{"key":"2025041601022992500_B19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025041601022992500_B20","doi-asserted-by":"publisher","first-page":"e13243","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2025041601022992500_B21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug Chem"},{"key":"2025041601022992500_B22","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2025041601022992500_B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2018.0747","article-title":"Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment","volume":"29","author":"Gait","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"2025041601022992500_B24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"2025041601022992500_B25","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody\u2013oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2025041601022992500_B26","doi-asserted-by":"publisher","first-page":"14868","DOI":"10.1021\/acs.jmedchem.4c00803","article-title":"Structure-activity relationship of antibody\u2013oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-phosphorodiamidate morpholino oligomer conjugates for drug development","volume":"67","author":"Cochran","year":"2024","journal-title":"J Med Chem"},{"key":"2025041601022992500_B27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/humu.22390","article-title":"The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia","volume":"34","author":"Bladen","year":"2013","journal-title":"Hum Mutat"},{"key":"2025041601022992500_B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skeletal Muscle"},{"key":"2025041601022992500_B29","doi-asserted-by":"publisher","first-page":"e0204485","DOI":"10.1371\/journal.pone.0204485","article-title":"A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures","volume":"13","author":"Hiller","year":"2018","journal-title":"PLoS One"},{"key":"2025041601022992500_B30","doi-asserted-by":"publisher","first-page":"e0162467","DOI":"10.1371\/journal.pone.0162467","article-title":"Digital droplet PCR for the absolute quantification of exon skipping induced by antisense oligonucleotides in (Pre-)clinical development for Duchenne muscular dystrophy","volume":"11","author":"Verheul","year":"2016","journal-title":"PLoS One"},{"key":"2025041601022992500_B31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/2472555218761102","article-title":"MyoScreen, a high-throughput phenotypic screening platform enabling muscle drug discovery","volume":"23","author":"Young","year":"2018","journal-title":"SLAS Discovery"},{"key":"2025041601022992500_B32","doi-asserted-by":"crossref","DOI":"10.17226\/25801","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011","edition":"8th ed"},{"key":"2025041601022992500_B33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR\/Cas9 gene editing therapy","volume":"4","author":"Young","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"2025041601022992500_B34","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1074\/jbc.M709410200","article-title":"Generation and characterization of transgenic mice with the full-length human DMD gene","volume":"283","author":"t\u00a0Hoen","year":"2008","journal-title":"J Biol Chem"},{"key":"2025041601022992500_B35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/nat.2014.0528","article-title":"Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides","volume":"25","author":"Burki","year":"2015","journal-title":"Nucleic Acid Ther"},{"key":"2025041601022992500_B36","doi-asserted-by":"publisher","first-page":"e0195850","DOI":"10.1371\/journal.pone.0195850","article-title":"Use of capillary western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy","volume":"13","author":"Beekman","year":"2018","journal-title":"PLoS One"},{"key":"2025041601022992500_B37","doi-asserted-by":"publisher","first-page":"e0120058","DOI":"10.1371\/journal.pone.0120058","article-title":"In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy","volume":"10","author":"Echigoya","year":"2015","journal-title":"PLoS One"},{"key":"2025041601022992500_B38","doi-asserted-by":"publisher","first-page":"39094","DOI":"10.1038\/srep39094","article-title":"Targeted RNA-seq profiling of splicing pattern in the DMD gene: exons are mostly constitutively spliced in human skeletal muscle","volume":"7","author":"Bouge","year":"2017","journal-title":"Sci Rep"},{"key":"2025041601022992500_B39","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1212\/WNL.0000000000001025","article-title":"Dystrophin quantification: biological and translational research implications","volume":"83","author":"Anthony","year":"2014","journal-title":"Neurology"},{"key":"2025041601022992500_B40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/humu.23561","article-title":"DMD genotype correlations from the Duchenne Registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype","volume":"39","author":"Wang","year":"2018","journal-title":"Hum Mutat"},{"key":"2025041601022992500_B41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JND-140002","article-title":"Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping","volume":"1","author":"van","year":"2014","journal-title":"J Neuromusc Dis"},{"key":"2025041601022992500_B42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1050-1738(02)00166-4","article-title":"Intermediate filaments and the function of the dystrophin\u2013protein complex","volume":"12","author":"Blake","year":"2002","journal-title":"Trends Cardiovasc Med"},{"key":"2025041601022992500_B43","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"2025041601022992500_B44","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s42003-022-03980-y","article-title":"The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction","volume":"5","author":"Wilson","year":"2022","journal-title":"Commun Biol"},{"key":"2025041601022992500_B45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13023-021-01837-x","article-title":"Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2025041601022992500_B46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025041601022992500_B47","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1038\/s41598-017-04520-z","article-title":"A comprehensive mouse transcriptomic BodyMap across 17 tissues by RNA-seq","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"2025041601022992500_B48","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025041601022992500_B49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"2025041601022992500_B50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/0192623317749452","article-title":"Characterizing adversity of lysosomal accumulation in nonclinical toxicity studies: results from the 5th ESTP International Expert Workshop","volume":"46","author":"Lenz","year":"2018","journal-title":"Toxicol Pathol"},{"key":"2025041601022992500_B51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/ppul.23215","article-title":"Cardiac phenotype determines survival in Duchenne muscular dystrophy","volume":"51","author":"Birnkrant","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2025041601022992500_B52","doi-asserted-by":"publisher","first-page":"e006340","DOI":"10.1161\/JAHA.117.006340","article-title":"Predictors of death in adults with Duchenne muscular dystrophy-associated cardiomyopathy","volume":"6","author":"Cheeran","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025041601022992500_B53","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2025041601022992500_B54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025041601022992500_B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J Control Release"},{"key":"2025041601022992500_B56","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","article-title":"Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing","volume":"18","author":"Hanson","year":"2021","journal-title":"RNA Biol"},{"key":"2025041601022992500_B57","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative antisense screening and optimization for Exon 51 skipping in Duchenne muscular dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol Ther"},{"key":"2025041601022992500_B58","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s11095-021-03118-5","article-title":"Pharmacokinetic\/pharmacodynamic modeling of a cell-penetrating peptide phosphorodiamidate morpholino oligomer in mdx mice","volume":"38","author":"Mukashyaka","year":"2021","journal-title":"Pharm Res"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/53\/6\/gkaf241\/62862122\/gkaf241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/53\/6\/gkaf241\/62862122\/gkaf241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:03:47Z","timestamp":1744779827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkaf241\/8106305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaf241","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,11]]},"published":{"date-parts":[[2025,3,20]]},"article-number":"gkaf241"}}